Literature DB >> 22091998

Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure.

Vincenzo De Filippis1, Stefano Lancellotti, Fabio Maset, Barbara Spolaore, Nicola Pozzi, Giovanni Gambaro, Laura Oggianu, Lorenzo A Calò, Raimondo De Cristofaro.   

Abstract

CKD (chronic kidney disease) is a life-threatening pathology, often requiring HD (haemodialysis) and characterized by high OS (oxidative stress), inflammation and perturbation of vascular endothelium. HD patients have increased levels of vWF (von Willebrand factor), a large protein (~240 kDa) released as UL-vWF (ultra large-vWF polymers, molecular mass ~20000-50000 kDa) from vascular endothelial cells and megakaryocytes, and responsible for the initiation of primary haemostasis. The pro-haemostatic potential of vWF increases with its length, which is proteolytically regulated by ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin motifs 13), a zinc-protease cleaving vWF at the single Tyr1605-Met1606 bond, and by LSPs (leucocyte serine proteases), released by activated PMNs (polymorphonuclear cells) during bacterial infections. Previous studies have shown that in vitro oxidation of Met1606 hinders vWF cleavage by ADAMTS-13, resulting in the accumulation of UL-vWF that are not only more pro-thrombotic than shorter vWF oligomers, but also more efficient in binding to bacterial adhesins during sepsis. Notably, HD patients have increased risk of developing dramatic cardiovascular and septic complications, whose underlying mechanisms are largely unknown. In the present study, we first purified vWF from HD patients and then chemically characterized its oxidative state. Interestingly, HD-vWF contains high carbonyl levels and increased proportion of UL-vWF polymers that are also more resistant to ADAMTS-13. Using TMS (targeted MS) techniques, we estimated that HD-vWF contains >10% of Met1606 in the sulfoxide form. We conclude that oxidation of Met1606, impairing ADAMTS-13 cleavage, results in the accumulation of UL-vWF polymers, which recruit and activate platelets more efficiently and bind more tightly to bacterial adhesins, thus contributing to the development of thrombotic and septic complications in CKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22091998     DOI: 10.1042/BJ20111798

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  7 in total

Review 1.  Regulation of thrombosis and vascular function by protein methionine oxidation.

Authors:  Sean X Gu; Jeff W Stevens; Steven R Lentz
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

Review 2.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 3.  Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis.

Authors:  Ashwag Saleh Alsharidah
Journal:  Blood Res       Date:  2022-05-30

4.  Effect of Vitamin D Status on Von Willebrand Factor and ADAMTS13 in Diabetic Patients on Chronic Hemodialysis.

Authors:  Keren Cohen-Hagai; Gloria Rashid; Yael Einbinder; Meital Ohana; Sydney Benchetrit; Tali Zitman-Gal
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

5.  Von Willebrand Factor Multimers and the Relaxation Response: A One-Year Study.

Authors:  Carlo Dal Lin; Laura Acquasaliente; Sabino Iliceto; Vincenzo De Filippis; Giuseppe Vitiello; Francesco Tona
Journal:  Entropy (Basel)       Date:  2021-04-10       Impact factor: 2.524

6.  The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus.

Authors:  Laura Oggianu; Stefano Lancellotti; Dario Pitocco; Francesco Zaccardi; Paola Rizzo; Francesca Martini; Giovanni Ghirlanda; Raimondo De Cristofaro
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 7.  Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.

Authors:  Stefano Lancellotti; Maria Basso; Raimondo De Cristofaro
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-09-02       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.